Echo Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 28 5 447 428
Cost of Revenue - - - -
Gross Profit 28 5 447 428
Operating Expenses
Research and Development 11,299 8,671 3,796 2,579
Sales, General and Admin. 8,365 6,374 4,906 2,760
Non-Recurring Items - - - -
Other - - - -
Operating Income (19,636) (15,040) (8,255) (4,910)
Income From Continuing Operations
Add'l Income/Expense Items 4,469 3,213 (1,761) 801
Earnings Before Interest and Tax (15,167) (11,827) (10,014) (4,293)
Interest Expense 3,900 505 14 38
Earnings Before Tax (19,067) (12,332) (10,028) (4,331)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (19,067) (12,332) (10,030) (4,147)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (19,067) (12,332) (10,030) (4,147)
Preferred Stock and Other Adjustments (371) - (6,693) (132)
Net Income Applicable to Common Shareholders (19,439) (12,332) (16,722) (4,278)